Azathioprine increases risk of pancreatitis in children with IBD
Use of azathioprine is associated with a six-fold increased risk of acute pancreatitis in children with inflammatory bowel disease (IBD) during the first 90 days following start of treatment suggesting the need for regular and rigorous monitoring, as per a new study reported Jan. 23, 2019 in The Lancet Child and Adolescent Health.
Read the full story.
Create a free account.
Sign Up to instantly read 30000+ free Articles & 1000+ Case Studies